(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $9 to $19, according to analysts polled by Capital IQ. (MT...
Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $9 to $19, according to analysts polled by Capital IQ. (MT...
| Address | 840 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.857.320.2200 |
| Number of Employees | 49 |
| Recent SEC Filing | 05/25/2022 8-K |
| President, Chief Executive Officer & Director | William R. Hinshaw |
| Chief Financial Officer & Senior Vice President | Robert W. Crane |
| Chief Scientific Officer, Senior VP-R&D | Tony Tramontin |
| Chief Medical Officer & Senior Vice President | Margaret Koziel |
| Price Open | $1.61 |
| Previous Close | $1.67 |
| 52 Week Range | $1.35 - 5.90 |
| Market Capitalization | $87.8 M |
| Shares Outstanding | 52.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -202.08% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
